Pro-Pharmaceuticals adds new member to board of directors
NEWTON, Mass. A company that develops carbohydrate-based drugs to treat cancer and fibrosis has made a new executive appointment.
Pro-Pharmaceuticals announced Monday the appointment of Prism Technologies founder Arthur Greenberg to its board of directors.
“We are very pleased to have Mr. Greenberg join our board of directors,” Pro-Pharmaceuticals CEO Theodore Zucconi said in a statement. “Bobby is a highly regarded executive with a wealth of business experience.”
The company is planning to commercialize one of its products, Davanat, a colorectal and biliary cancer treatment.
Wild Child provides natural way to ‘Quit Nits’
LOS ANGELES Wild Child, an Australian-based natural healthcare products company showcased its Quit Nits head lice products at ECRM Health Care.
According to the company, from a survey of 1,002 parents of children ages 6 to 13, 69% of parents said it was extremely important that any lice solution they buy not contain any toxic chemicals. And 61% responded that the product should be safe for use by pregnant women. In addition, over 3-in-5 parents (64%) were bothered by the fact that many head lice treatments currently contain toxic ingredients with possible negative side effects.
Teva launches ‘Patient First’ project
WASHINGTON The world’s largest generic drug maker has started an initiative to tell stories of Americans who have difficulty paying for their prescription medications, and push for a regulatory approval pathway for biosimilars.
Teva Pharmaceuticals USA announced Thursday the “Patient First” project, part of its broader Year of Affordable Healthcare campaign.
One story is of Rob Day, who was diagnosed at age 19 with the rare blood disorder paroxysmal nocturnal hemoglobinuria, for which he must take an unspecified biotech drug that costs him $389,000 a year. Teva said a Food and Drug Administration approval pathway for biosimilars would help lower prices for drugs like the one Day takes.